Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia

Authors

Niraj Neupane, Rochester Regional HealthFollow
Soon K. Low, Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Himal Kharel, Rochester Regional HealthFollow
Sanket Bhattarai, Mayo Clinic, Rochester, Minnesota, USA.
Sangharsha Thapa, Department of Medicine, Westchester Medical Center, New York Medical College, Westchester, New York, USA.
Amir Mahmoud, Rochester Regional HealthFollow
Nishant B. Pokhrel, Department of Internal Medicine, Norwalk Hospital, Norwalk, Connecticut, USA.
Mohammad Ammad Ud Din, Department of Hematology and Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Peter Kouides, Rochester Regional HealthFollow

Department

Internal Medicine

Additional Department

Oncology and Hematology

Document Type

Article

Publication Title

American Journal of Hematology

First Page

E26

Last Page

E28

DOI

10.1002/ajh.27148

Volume

99

Issue

1

Publication Date

1-1-2024

Medical Subject Headings

Humans; Thrombocythemia, Essential (complications, genetics); Thrombosis (genetics, complications); Mutation; Janus Kinase 2 (genetics)

PubMed ID

37950856

Recommended Citation

Neupane, N., Low, S. K., Kharel, H., Bhattarai, S., Thapa, S., Mahmoud, A., Pokhrel, N. B., Ammad Ud Din, M., & Kouides, P. (2024). Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia. American Journal of Hematology, 99 (1), E26-E28. https://doi.org/10.1002/ajh.27148